Composition : Trizidim® 250 mg IM / IV : Ceftazidime USP 250 mg.
Trizidim® 500 mg IM / IV : Ceftazidime USP 500 mg.
Trizidim® 1 g IM / IV : Ceftazidime USP 1 g.
Water for injection : Each ampoule contains 5 ml or 10 ml sterile water for injection BP for reconstitution.
Indications : Lower respiratory tract infections, Skin & skin structure infections, Urinary tract infections, Bacterial septicemia, Bone & joint infections, Gynecologic infections, Intra-abdominal infections, Central nervous system infections Infections associated with haemo-and peritoneal dialysis and with continuous ambulatory peritoneal dialysis (CAPD).
Dosage & Administration :
|
|
Dose
|
Frequency
|
|
Adults
|
|
|
|
Usual recommended dosage
|
1 g IV or IM
|
8-12 hourly
|
|
Uncomplicated pneumonia
|
500mg-1gIV or IM
|
8 hourly
|
|
Lung infections
|
30-35 mg /kg IV
|
8 hourly
|
|
Mild skin and skin-structure infections
|
500 mg – 1 g IV or IM
|
8 hourly
|
|
Complicated urinary tract infections
|
500 mg IV or IM
|
12 hourly
|
|
Bone & joint infections, severe
life-threatening infections especially in
immunocompromised patients, Meningitis,
Serious gynecologic and intra-abdominal infections
|
2 g IV
|
8 hourly
|
|
Neonates (0-4 weeks)
|
30 mg/kg IV
|
12 hourly
|
|
Infants and children
(1 month – 12 years)
|
30-50 mg/kg IV to maximum
of 6 g per day
|
8 hourly
|
Dose in dialysis : 1 g loading dose followed by 1 g after each hemodialysis period.
